Articles |
From the Departments of Metabolic Medicine (T.M., M.S., S.K., T.B., T.T., H.M., M.S.) and Biochemistry (H.H., S.H.), Kumamoto University School of Medicine, Kumamota, Japan.
Correspondence to Takeshi Matsumura, MD, Department of Metabolic Medicine, Kumamoto University School of Medicine, 1-1-1 Honjo, Kumamoto 860, Japan.
| Abstract |
|---|
|
|
|---|
Key Words: protein kinase C G proteins oxidized LDL macrophage growth atherosclerosis
| Introduction |
|---|
|
|
|---|
One of the characteristic events in the development of atherosclerotic lesions in arterial walls is the growth of cellular components. In particular, proliferating foam cells found in the advanced or mature stages of atherosclerosis are derived from smooth muscle cells.1 However, recent reports emphasized that a proportion of foam cells proliferating in the atherosclerotic lesions are also derived from macrophages.5 6 7 Gordon et al5 demonstrated that 27% of cells positive for proliferating cell nuclear antigen in human coronary atherosclerotic lesions corresponded to macrophages. Furthermore, Rosenfeld and Ross6 demonstrated that in aortic atherosclerotic plaques of both Watanabe heritable hyperlipidemic rabbits and cholesterol-fed rabbits, 30% of cells that incorporated [3H]thymidine were derived from macrophages. Since macrophage-derived foam cells play an important role in the development of atherosclerotic lesions, it seems reasonable to expect that macrophage growth might be linked to atherosclerotic processes, probably by enhancing its progression.
Along with this line of thinking, we originally observed the capacity of Ox-LDL to stimulate the growth of starch-induced mouse peritoneal macrophages.8 Our subsequent studies showed that the Ox-LDLinduced macrophage growth is also observed with other macrophages, such as mouse resident peritoneal macrophages,9 rat resident peritoneal macrophages,10 and human monocyte-derived macrophages.11 Moreover, our biochemical studies showed that endocytic internalization of lyso-PC, a major modified lipid moiety of Ox-LDL, into cells through the SR-AI/AII is essential for Ox-LDLinduced macrophage growth.12 Considered together, these findings strongly suggest that to promote macrophage growth, Ox-LDL probably acts as a growth factor to macrophages by inducing certain intracellular signaling pathways. The present study was undertaken to characterize Ox-LDLinduced intracellular signaling pathways for the growth of mouse resident macrophages. The results indicate that a rise in intracellular calcium ion and the uptake of lyso-PC through the scavenger receptors are two potential pathways for activation of PKC that might be involved in Ox-LDLinduced macrophage growth.
| Methods |
|---|
|
|
|---|
Lipoproteins and Their Modifications
Human LDL (d=1.019 to 1.063 g/mL) was isolated
by sequential ultracentrifugation from the plasma of
normolipidemic subjects after overnight fasting.13 LDL was
dialyzed against 0.15 mol/L NaCl and 1 mmol/L EDTA,
pH 7.4. Acetyl-LDL was prepared by chemical modification of LDL with
acetate anhydride.14 Acetyl-LDL (2 mg) was dialyzed
against Tris-HCl (pH 7.4) and treated then with 5 U/mL PLA2 for 2 hours
at 37°C in Tris-HCl (pH 7.4) containing 2 mmol/L
CaCl2.15 Then, PLA2 was removed from acetyl-LDL by
ultracentrifugation. Ox-LDL was prepared by incubation
of LDL with 5 µmol/L CuSO4 for 20 hours at
37°C followed by the addition of 1 mmol/L EDTA and
cooling.16 17 The concentration of proteins was determined
by BCA protein assay reagent (Pierce) using bovine serum
albumin as a standard.18 Lipid contents of
lipoproteins were determined on a Hitachi 7450 automatic
analyzer using standard enzymatic methods.19 20 21
Determination of PC and lyso-PC was performed by the method described
by Bartlett.22 Endotoxin levels associated with these
lipoproteins were measured by a commercially available kit (Toxicolor
system, Seikagaku Corp).
Tritiated Thymidine Incorporation Assay
Peritoneal macrophages were collected from nonstimulated
male C3H/He mice (25 to 30 g) and suspended in RPMI-1640 medium
(Nissui Seiyaku Co) supplemented with 10% heat-inactivated
fetal bovine serum (Life Technologies, Inc), streptomycin (0.1
mg/mL), and penicillin (100 U/mL) (medium A). The peritoneal
cells were adjusted to 4x105 cells per milliliter for the
[3H]thymidine incorporation assay.9 Cell
suspensions (0.1 mL) were dispersed in each well of 96-well
tissue-culture plates (6.4 mm in diameter, Falcon) and incubated
for 90 minutes at 37°C. The nonadherent cells were removed by washing
three times with 0.1 mL of prewarmed medium A. More than 98% of
adherent cells were confirmed to be macrophages by both Giemsa
staining and carbon particle uptake.9 These
macrophages were cultured at 37°C in 0.1 mL of medium A in
the presence of the test lipoproteins without a medium change. Eighteen
hours before the termination of the experiments, 10 µL of 10 µCi/mL
[3H]thymidine was added to each well and incubated for 18
hours at 37°C. The medium was discarded, and the cells were dissolved
in 0.1 mL of 0.5% sodium dodecyl sulfate and subsequently
precipitated with 0.1 mL of ice-cold 10% trichloroacetic acid. The
resulting trichloroacetic acidinsoluble material was collected on
filters with Labomash LM-101 (Labo Science). The filters were dried,
and their radioactivity was counted in a liquid scintillation
spectrophotometer.9
Cell-Counting Assay
Mouse peritoneal macrophages were collected as described
above. The peritoneal cells were adjusted to 2x104 cells
per milliliter, and 1 mL of cell suspension was dispersed in each well
of 24-well tissue-culture plates (16 mm in diameter, Falcon) and
incubated for 90 minutes at 37°C. The nonadherent cells were removed
by washing three times with 1 mL of prewarmed medium A. These
macrophages were cultured at 37°C in 1 mL of medium A with or
without the test lipoproteins. After incubation for 7 days without
medium change, the adherent cells in triplicate wells were lysed in 1%
(wt/vol) Triton X-100, and the number of naphthol blue-blackstained
nuclei were counted in a hemocytometer as described
previously.9
Measurement of Cytosolic Free Calcium Concentration
The fluorescent calcium indicator fura 2 was used to
monitor changes in cytosolic free calcium concentration
([Ca2+]i) in mouse peritoneal
macrophages.23 The cells (1x104 cells
per well) were washed three times with 2 mL of Krebs-Ringer HEPES
solution (in mmol/L: 128 NaCl, 5 KCl, 2.7 CaCl2, 1.2 MgSO4,
1 Na2HPO4, 10 glucose, and 20 HEPES, pH 7.4),
followed by exposure to 4 µmol/L fura 2-AM in 2 mL of
Krebs-Ringer HEPES solution for 15 minutes at 25°C. The cells were
washed three times with Krebs-Ringer HEPES solution and incubated with
2 mL of Krebs-Ringer HEPES solution at 37°C. Fluorescence
signals were monitored on an ARGUS-50/CA system (Hamamatsu) at
excitation wavelengths of 340 and 380 nm and an emission wavelength of
505 nm. The cells were then stimulated by the test lipoproteins. In
some experiments, the cells were pretreated for 5 minutes with PTX
before the addition of lipoproteins.
Assay of PKC Activity
PKC activity in macrophages was assayed by MESACUP
Protein Kinase Assay Kit (Medical and Biological Laboratories).
Macrophages (1x107 cells per well) in 2 mL of
serum-free RPMI-1640 medium were treated with 50 µg/mL
lipoproteins for the indicated times. The cells were washed three times
with ice-cold PBS and detached from the plates with a rubber policeman.
Cells were suspended in 1 mL of sample preparation buffer (in
mmol/L: 5 EDTA, 10 EGTA, 50 2-mercaptoethanol, 1 PMSF, 10
benzamidine, and 50 Tris-HCl, pH 7.5) and sonicated for 30 seconds at
4°C by SONIFIER (Branson Sonic Power Co). Homogenates
were centrifuged at 100 000g for 1 hour at 4°C.
The supernatant was discarded and the precipitates were resuspended in
1 mL of buffer and used as the membrane fractions. The PKC activity in
the membrane fractions was measured as follows. Twelve microliters of
membrane fractions (5 µg) was added to 108 µL of component buffer
(final concentration of reaction mixture: 3 mmol/L
MgCl2, 0.1 mmol/L ATP, 2 mmol/L
CaCl2, 50 µg/mL
phosphatidylserine, 0.5 mmol/L EDTA,
1 mmol/L EGTA, 5 mmol/L 2-mercaptoethanol, and
25 mmol/L Tris-HCl, pH 7.0). One hundred microliters of
this mixture was transferred to each well coated with PKC-specific
peptide (RFARKGSLRQKNV) with a multichannel pipette. Each well was
incubated at 25°C for 5 minutes, and the reaction was terminated by
the addition of 100 µL of 20% H3PO4,
followed by washing five times with 400 µL of PBS. To each well was
added 100 µL of biotinylated antiphosphorylated
tyrosine antibody (2B9), incubated at 25°C for 60 minutes, and washed
five times with PBS. To each well was then added 100 µL of
peroxidase-conjugated streptavidin, and samples were incubated at
25°C for 60 minutes and washed five times with PBS, followed by the
addition of 100 µL of H2O2 and
o-phenylenediamine. After incubation at
25°C for 5 minutes, 100 µL of 20% H3PO4
was added, and the absorbance at 492 nm was read with a microplate
reader. Nonspecific serine/threonine-kinase activities were measured
both in the absence of phosphatidylserine and in
the presence of 2 mmol/L EGTA in component buffer. The
enzyme activity specific for conventional PKC was quantitated by
subtracting the nonspecific serine/threonine-kinase activities from
total kinase activity in membrane fraction.
Miscellaneous
Data were expressed as mean±SD. Differences between groups were
compared for statistical significance using the Student's t
test. A probability value less than 5% was considered significant. The
experimental protocol was approved by the Human Ethics Review Committee
and the Ethics Review Committee for Animal Experimentation of our
institution.
| Results |
|---|
|
|
|---|
|
Effect of Ox-LDL on Intracellular Calcium Concentration in
Macrophages
To elucidate the intracellular signaling pathways in
Ox-LDLinduced macrophage proliferation, we first examined
[Ca2+]i in macrophages using digital
fluorescent microscopy. Addition of Ox-LDL to these
macrophages resulted in an instantaneous rise in
[Ca2+]i followed by a return to the baseline
level within 5 minutes (Fig 1A
). The
effect of Ox-LDL on [Ca2+]i was dose
dependent (Fig 2
). In contrast, both LDL
and acetyl-LDL had no effect on [Ca2+]i in
these cells (Figs 1B
, 1C
, and 2
). Moreover, PLA2-treated acetyl-LDL,
which possessed growth-stimulating activity for macrophages
(Table 2
), did not induce a rise in
[Ca2+]i (Fig 1D
). Even when the cells were
pretreated with acetyl-LDL, Ox-LDL retained its capacity to induce a
rise in [Ca2+]i in these macrophages
(Fig 1E
). Pretreatment of macrophages with thapsigargin
significantly inhibited Ox-LDLinduced rise in
[Ca2+]i (Fig 1F
), suggesting that the rise in
[Ca2+]i was derived from intracellular
calcium store. This notion was supported by the observation that
Ox-LDLinduced rise in [Ca2+]i was inhibited
neither by calcium channel blockers, such as nifedipine and
nicardipine nor by calcium chelator EGTA (data not
shown).
|
|
|
Effect of PTX on Intracellular Calcium Concentration and
Macrophage Proliferation
In the next step, we compared the effects of PTX on
Ox-LDLinduced [Ca2+]i rise and subsequent
macrophage growth. Pretreatment of macrophages with 10
ng/mL PTX for 5 minutes inhibited Ox-LDLinduced
[Ca2+]i rise (Fig 3
). As shown in Fig 4
, PTX significantly inhibited
Ox-LDLinduced increase in [3H]thymidine incorporation
in a dose-dependent manner up to 10 ng/mL, with a maximal
inhibition of macrophage growth of 50%. Under these
conditions, PTX alone up to 100 ng/mL did not affect cell
viability determined by both the cell-counting assay using trypan blue
staining and the release of lactic dehydrogenase from cells (data not
shown). Parallel experiments with the cell-counting assay also showed
that the cell number increased by 20 µg/mL Ox-LDL was
inhibited by 52% with 10 ng/mL PTX (Table 2
). In contrast,
PLA2-treated acetyl-LDLinduced increase in cell number was not
affected by PTX (Table 2
). These results suggested that the initial but
transient increase in [Ca2+]i induced by
Ox-LDL was probably related to Ox-LDLinduced macrophage
growth and also suggested the presence of other signaling pathway(s)
for PLA2-treated acetyl-LDLinduced macrophage growth.
|
|
Involvement of PKC in Ox-LDLInduced Macrophage Growth
Fig 5
shows the time-course study of
the membrane PKC activity. After the addition of 20 µg/mL
Ox-LDL to these cells, the enzyme activity increased 2.2-fold above the
basal level at 5 minutes and further increased to 4.4-fold above the
basal level at 10 minutes, followed by a rapid decline close to the
baseline level at 20 minutes. However, PKC seemed to be still
activated to some extent even 30 minutes after the addition of
Ox-LDL. PLA2-treated acetyl-LDL also activated the membrane
PKC, whose level was less than that activated by Ox-LDL. Both
LDL and acetyl-LDL failed to stimulate the membrane PKC activity in
these cells (Fig 5
).
|
To elucidate the role of PKC activation in Ox-LDLinduced
macrophage growth, the effect of a PKC inhibitor,
calphostin C, on Ox-LDLinduced macrophage growth was
examined. On incubation of macrophages with different
concentrations of calphostin C, the Ox-LDLinduced increase in
[3H]thymidine incorporation was suppressed in a
dose-dependent manner, with 50% inhibition of 50 nmol/L
calphostin C and the maximal inhibition of 80% at 200 nmol/L
(Fig 6
). Incubation of
macrophages with 2 or 10 µmol/L H-7, another PKC
inhibitor, also suppressed Ox-LDLinduced increase in
[3H]thymidine incorporation by 80% (Fig 6
). On the other
hand, HA-1004, an inhibitor of cyclic GMPdependent and
cyclic AMPdependent protein kinase, and H-89, an
inhibitor of cyclic AMPdependent protein kinase, had
almost no effect on this system. To further confirm the results
obtained by [3H]thymidine incorporation assay, we also
assessed the effect of calphostin C on Ox-LDLinduced
macrophage growth by cell counting. As shown in Table 3
, the increased number of cells induced
by Ox-LDL was 1.9-fold above the basal level. When macrophages
were cultured under the identical conditions but in the presence of
calphostin C, the increase in cell numbers was only 1.2-fold above the
basal level, indicating the effective suppression of cell growth by
this drug. Moreover, calphostin C significantly inhibited the increased
number of cells induced by PLA2-treated acetyl-LDL (Table 3
). Under
these conditions, calphostin C had no cytotoxic effect on these cells;
more than 95% of the cells were viable, as confirmed by microscopic
examination after trypan blue staining and incorporation of
[3H]leucine into protein (data not shown). These results
support a possible role of PKC but not cyclic GMPdependent and cyclic
AMPdependent protein kinase in Ox-LDLinduced macrophage
growth. In support for this notion, TPA alone could induce
macrophage growth, which was suppressed by calphostin C (Table 3
), and when the PKC activity of these macrophages was
downregulated by 24 hours' pretreatment with 1 µmol/L
TPA, Ox-LDLinduced macrophage growth was significantly
inhibited (data not shown).
|
|
| Discussion |
|---|
|
|
|---|
It is likely that the increased [Ca2+]i is
derived from intracellular calcium store, because pretreatment of
macrophages with thapsigargin significantly inhibited
Ox-LDLinduced rise in [Ca2+]i (Fig 1F
) and
because neither calcium channel blockers nor EGTA affected
Ox-LDLinduced calcium rise (data not shown). This notion was
supported by Shackelfold et al,28 who demonstrated that
Ox-LDL initiated a rapid increase in phosphatidylinositol bisphosphate
hydrolysis into inositol triphosphate, which in turn enhanced calcium
release from the endoplasmic reticulum in mouse macrophages.
Our results also showed that Ox-LDLinduced
[Ca2+]i rise was completely inhibited by PTX
(Fig 3
). Moreover, PTX inhibited Ox-LDLinduced macrophage
growth by 50% (Fig 4
and Table 2
). These results suggest that the
rapid release of Ca2+ from the endoplasmic reticulum is
likely to be involved in Ox-LDLinduced macrophage
proliferation.
The inhibition by PTX of Ox-LDLinduced
[Ca2+]i rise and macrophage growth
(Figs 3
and 4
, Table 2
) suggests the presence of a G-proteincoupled
Ox-LDL receptor that initiates the intracellular signal(s) and finally
leads to macrophage growth. Most G-proteinlinked receptors
identified so far have a common structure: seven membrane-spanning
domains connected by extracellular and intracellular
loops.29 According to a general model of
chemokine-mediated signal transduction events in phagocytes, an
appropriate ligand-receptor interaction causes the activation of a
PTX-sensitive G-protein with subsequent induction of phospholipase C
activity.30 This leads to the accumulation of both
diacylglycerol and cytosolic inositol trisphosphate31 ; the
former directly stimulates PKC activity, whereas the latter in turn
initiates mobilization of intracellular Ca2+ from the
endoplasmic reticulum, leading to PKC activation.32 33
Several scavenger receptors have been reported, which include the
SR-AI/AII,34 the Fc receptor,35
CD-36,36 SR-BI,37 SR-CI,38
macrosialin,39 and MARCO.40 However, none of
them posses a seven-transmembrane domain, a characteristic feature of
the G-proteincoupled receptor. Further studies are needed, therefore,
to identify the receptor involved in the Ox-LDLinduced rise in
[Ca2+]i.
Considering the findings of this and our previous
studies,9 12 we could assume the intracellular events that
lead to macrophage growth. Two intracellular signaling
pathways, activation of G-protein and the endocytic internalization of
lyso-PC, are responsible for Ox-LDLmediated macrophage
growth. In the first pathway, binding of Ox-LDL to its receptor on
macrophage plasma membranes initiates activation of a
PTX-sensitive G-protein and then induces phospholipase C activity, to
produce diacylglycerol and inositol triphosphate. PKC is known to be
activated directly by diacylglycerol or indirectly by inositol
triphosphate via an increase in [Ca2+]i. Well
established as major endocytic receptors, the SR-AI/AII are also known
to modulate a variety of macrophage functions, such as
endocytosis of modified proteins,41 cell
adhesion,42 and the release of lipoprotein
lipase.43 However, intracellular signaling in response to
the ligand binding to the SR-AI/AII has not been well established.
Recently, Claus et al44 demonstrated that acetyl-LDL could
activate PKC in P388D1 cells, which was inhibited by
polyinosinic acid, suggesting that the SR-AI/AII could induce
intracellular signals. However, since acetyl-LDL neither initiated
[Ca2+]i rise nor activated PKC in
mouse peritoneal macrophages (Figs 1
, 2
, and 5
), it seemed
unlikely that the receptors for acetyl-LDL, such as the SR-AI/AII,
MARCO, or SR-CI, are involved in increased
[Ca2+]i in Ox-LDLinduced macrophage
growth. An exact reason is unclear why the PKC was activated by
acetyl-LDL in P388D1 cells44 but not in mouse
macrophage in the present study. It could be due to the
difference in cell types and/or experimental conditions. However,
PLA2-treated acetyl-LDL could stimulate both PKC (Fig 5
) and
macrophage growth (Table 2
). Moreover, our recent study showed
that PLA2-treated acetyl-LDL did not show a significant
growth-stimulating capacity for the SR-AI/AII knockout mice, while
Ox-LDLinduced growth of these macrophages was 30% of that of
the wildtype littermates.12 These results suggest that
the internalization of lyso-PC in Ox-LDL into the cells through the
SR-AI/AII may also cause the activation of PKC, leading to
macrophage growth, whereas involvement of other receptors for
Ox-LDL could not be completely ruled out. This notion was supported by
the present results that PTX completely inhibited the rise in
[Ca2+]i but produced a 50% decrease in
macrophage growth (Figs 3
and 4
and Table 2
). Thus, two
independent pathways for PKC activation might act synergically to
induce Ox-LDLinduced macrophage growth. The PKC family is
reported to comprise at least 11 different subspecies of
serine/threonine protein kinase,45 such as conventional
PKC (
, ß1, ß2, and
) and novel PKC (
,
,
, and
).
Moreover, atypical subspecies of PKC were also reported
recently.45 The present study suggested the presence
of two pathways for activation of PKC. Thus, it is possible to
speculate that different PKC isozyme(s) were activated by these
pathways. Further studies using anti-PKC isoform-specific antibodies
are needed to identify the PKC isoform(s) involved in Ox-LDLinduced
macrophage growth.
The downstream signaling pathway from PKC activation to
macrophage proliferation remains unknown. However, two possible
pathways may be operating. First, PKC induces macrophage
proliferation directly via activation of MAP kinase. Recently, Kusuhara
et al46 demonstrated that Ox-LDL activated MAP
kinase of rat smooth muscle cells via PKC activation, suggesting that
Ox-LDLinduced macrophage growth might be mediated through
activation of MAP kinase after activation of PKC. Ox-LDL was also shown
to activate MAP kinase of human macrophages, but it was
not known whether activation of MAP kinase might be mediated by PKC
activation.46 Further studies will be needed to elucidate
the involvement of MAP kinase activation via PKC in Ox-LDLinduced
macrophage growth. Alternatively, PKC stimulates the induction
of growth factors such as macrophage-colony stimulating factor
or GM-CSF, which is able to induce macrophage growth in an
autocrine or paracrine fashion. In a series of preliminary experiments,
we noted that antiGM-CSF antibody caused 80% inhibition of
Ox-LDLinduced macrophage growth. Incubation with Ox-LDL
resulted in a significant release of GM-CSF from mouse peritoneal
macrophages in the culture medium, a process that was inhibited
by calphostin C (T. Biwa and S. Horiuchi, unpublished observations,
1997). Thus, it is likely that GM-CSF may act as a growth factor in
autocrine or paracrine fashion in Ox-LDLinduced macrophage
growth. The presence of a signaling pathway linking PKC activation to
GM-CSF induction has been described recently. Tsuboi et
al47 demonstrated that cooperation among AP-1,
NF-
B, and NF-ATbinding sequences was required for the induction
of GM-CSF, which was located downstream of PKC- and
Ca2+-signaling pathways in T lymphocytes. Moreover, Ares et
al48 reported that Ox-LDL could induce the activation of
AP-1 in smooth muscle cells. Therefore, it is reasonable to speculate
that induction of GM-CSF via activation of certain nuclear
transcription factors after PKC activation may be involved in
Ox-LDLinduced macrophage growth.
In conclusion, we have shown here that Ox-LDL initiates a rapid and transient increase in [Ca2+]i from intracellular calcium store and induces PKC activation in macrophages. PTX inhibits Ox-LDLinduced [Ca2+]i rise completely and Ox-LDLinduced macrophage growth significantly, whereas PKC inhibitors, such as calphostin C and H-7, show a significant inhibition for Ox-LDLinduced macrophage growth. On the other hand, PLA2-treated acetyl-LDL activates PKC and stimulates macrophage growth but failed to induce a rise in [Ca2+]i. Macrophage growth induced by PLA2-treated acetyl-LDL was inhibited by calphostin C but not by PTX. These results suggest that PKC activation by both the G-proteinmediated rise in [Ca2+]i and the endocytic internalization of lyso-PC plays an essential role in Ox-LDLinduced macrophage growth.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received January 28, 1997; accepted May 26, 1997.
| References |
|---|
|
|
|---|
2. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modification of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.[Medline] [Order article via Infotrieve]
3.
Palinski W, Rosenfeld ME., Ylä-Herttuala S,
Gurtner GC, Socher SS, Butler SW, Parthasarathy S, Carew TE, Steinberg
D, Witztum JL. Low density lipoprotein undergoes oxidative
modification in vivo. Proc Natl Acad Sci U S A. 1989;86:1372-1376.
4. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086-1095.
5.
Gordon D, Reidy MA, Benditt EP, Schwartz SM.
Cell proliferation in human coronary arteries.
Proc Natl Acad Sci U S A. 1990;87:4600-4604.
6.
Rosenfeld ME, Ross R. Macrophage and
smooth muscle cell proliferation in atherosclerotic lesions of WHHL and
comparably hypercholesterolemic fat-fed
rabbits. Arteriosclerosis. 1990;10:680-687.
7. Spagnoli LG, Orlandi A, Santeusanio G. Foam cells of the rabbit atherosclerotic plaque arrested in metaphase by colchicine show a macrophage phenotype. Atherosclerosis. 1991;88:87-92.[Medline] [Order article via Infotrieve]
8.
Yui S, Sasaki T, Miyzaki A, Horiuchi S, Yamazaki
M. Induction of murine macrophage growth by modified
LDLs. Arterioscler Thromb. 1993;13:331-337.
9.
Sakai M, Miyazaki A, Hakamata H, Sasaki T, Yui S,
Yamazaki M, Shichiri M, Horiuchi S. Lysophosphatidylcholine
plays an essential role in the mitogenic effect of oxidized
low density lipoprotein on murine macrophages.
J Biol Chem. 1994;269:31430-31435.
10. Sato Y, Kobori S, Sakai M, Yano T, Higashi T, Matsumura T, Morikawa W, Terano T, Miyazaki A, Horiuchi S, Shitiri M. Lipoprotein(a) induces cell growth in rat peritoneal macrophages through inhibition of transforming growth factor-ß activation. Atherosclerosis. 1996;125:15-26.[Medline] [Order article via Infotrieve]
11.
Sakai M, Miyazaki A, Hakamata H, Sasaki T, Yui S,
Yamazaki Y, Shichiri M, Horiuchi S. Lysophosphatidylcholine
potentiates the mitogenic activity of modified LDL for
human monocyte-derived macrophages. Arterioscler
Thromb Vasc Biol. 1996;16:600-605.
12.
Sakai M, Miyazaki A, Hakamata H, Kodama T, Suzuki H,
Kobori S, Shichiri M, Horiuchi S. The scavenger receptor serves
as a route for internalization of lysophosphatidylcholine in oxidized
low density lipoprotein-induced macrophage
proliferation. J Biol Chem. 1996;271:27346-27352.
13.
Hakamata H, Miyazaki A, Sakai M, Suginohara Y, Sakamoto
Y, Horiuchi S. Species difference in cholesteryl ester cycle and
HDL-induced cholesterol efflux from macrophage foam
cells. Arterioscler Thromb. 1994;14:1860-1865.
14.
Miyazaki A, Sakai M, Suginohara Y, Hakamata H, Sakamoto
Y, Horiuchi S. Acetylated low density lipoprotein
reduces its ligand activity for the scavenger receptor after
interaction with reconstituted high density lipoprotein.
J Biol Chem. 1994;269:5264-5269.
15.
Quinn MT, Parthasarathy S, Steinberg D.
Lysophosphatidylcholine: a chemotactic factor for human monocyte and
its potential role in atherogenesis. Proc Natl Acad Sci
U S A. 1988;85:2805-2809.
16. Sakai M, Miyazaki A, Sakamoto Y, Horiuchi S. Cross-linking of apolipoprotein is involved in a loss of the ligand activity of high density lipoprotein upon Cu2+-mediated oxidation. FEBS Lett. 1992;314:199-202.[Medline] [Order article via Infotrieve]
17. Ohta T, Takata K, Horiuchi S, Morino Y, Matsuda I. Protective effect of lipoproteins containing apolipoprotein A-I on Cu2+-catalyzed oxidation of human low density lipoprotein. FEBS Lett. 1989;257:435-438.[Medline] [Order article via Infotrieve]
18. Miyazaki A, Rahim ATMA, Araki S, Morino Y, Horiuchi S. Chemical cross-linking alters high-density lipoprotein to be recognized by a scavenger receptor in rat peritoneal macrophages. Biochim Biophys Acta. 1991;1082:143-151.[Medline] [Order article via Infotrieve]
19. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1973;20:470-475.[Abstract]
20.
Spayd RW, Bruschi B, Burdick BA, Dappen GM, Eikenberry
JN, Esders TW, Figueras TW, Goodhue CT, LaRossa DD, Nelson RW, Rand RN,
Wu TW. Multilayer film elements for clinical analysis:
applications to representative chemical
determinations. Clin Chem. 1978;24:1343-1350.
21. Takayama M, Itoh S, Nagasaki T, Tanimizu I. A new enzymatic method for determination of serum choline-containing phospholipids. Clin Chim Acta. 1977;79:93-98.[Medline] [Order article via Infotrieve]
22.
Bartlett GR. Phosphorus assay in column
chromatography. J Biol Chem. 1959;234:466-468.
23.
Weisser B, Locher R, Mengden T, Vetter W.
Oxidation of low-density lipoprotein enhances its potential to increase
intracellular free calcium concentration in vascular smooth muscle
cells. Arterioscler Thromb. 1992;12:231-236.
24. Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumor promotion. Nature. 1984;308:693-698.[Medline] [Order article via Infotrieve]
25.
Nishizuka Y. Intracellular signaling by
hydrolysis of phospholipids and activation of protein kinase C.
Science. 1992;258:607-614.
26. Hamilton JA, Dientsman SR. Induction of macrophage DNA synthesis by phorbol esters. J Cell Physiol. 1981;106:445-450.[Medline] [Order article via Infotrieve]
27. Hamilton JA. Glucocorticoids and prostaglandins inhibit the induction of macrophage DNA synthesis by macrophage growth factor and phorbol ester. J Cell Physiol. 1983;115:67-74.[Medline] [Order article via Infotrieve]
28.
Shackelford RE, Misra UK, Florine-Casteel K, Sheau-Fung
T, Pizzo SV, Adams DO. Oxidized low density lipoprotein
suppresses activation of NF
B in macrophages via a pertussis
toxin-sensitive signaling mechanism. J Biol
Chem. 1995;270:3475-3478.
29. Birnbaumer L, Abramowitz J, Brown AM. Receptor-effector coupling by G proteins. Biochim Biophys Acta. 1990;1031:163-224.[Medline] [Order article via Infotrieve]
30. Thelen M, Peveri P, Kernen P, von Tscharner V, Walz A, Baggiolini M. Mechanism of neutrophil activation by NAF, a novel monocyte-derived peptide agonist. FASEB J. 1988;2:2702-2706.[Abstract]
31. Smith R.J, Sam LM, Leach KL, Justen JM. Postreceptor events associated with human neutrophil activation by interleukin-8. J Leukoc Biol. 1992;52:17-26.[Abstract]
32.
Pozzan T, Lew DP, Wollheim CB, Tsien RY. Is
cytosolic ionized calcium regulating neutrophil activation?
Science. 1983;221:1413-1415.
33.
Dewald B, Thelen M, Baggiolini M. Two
transduction sequences are necessary for neutrophil activation by
receptor agonists. J Biol Chem. 1988;263:16179-16184.
34.
Kodama T, Freeman M, Rohrer L, Zabrecky J, Matsudaira
P, Krieger M. Type I macrophage scavenger receptor
contains
-helical collagen-like coiled coils.
Nature. 1990;343:531-535.[Medline]
[Order article via Infotrieve]
35.
Stanton LW, White RT, Bryant CM, Protter AA, Endemann
G. A macrophage Fc receptor for IgG is also a receptor
for oxidized low density lipoprotein. J Biol
Chem. 1992;267:22446-22451.
36.
Endemann G, Stanton LW, Madden KS, Bryant CM, White RT,
Protter AA. CD36 is a receptor for oxidized low density
lipoprotein. J Biol Chem. 1993;268:11811-11816.
37.
Acton SL, Scherer PE, Lodish HF, Krieger M.
Expression cloning of SR-BI, a CD36-related class B scavenger
receptor. J Biol Chem. 1994;269:21003-21009.
38.
Pearson A, Lux A, Krieger M. Expression cloning
of dSR-CI, a class C macrophage-specific scavenger
receptor from Drosophila melanogaster. Proc
Natl Acad Sci U S A. 1995;92:4056-4060.
39.
Ramprasad MP, Fischer W, Witztum JL, Sambrano GR,
Quehenberger O, Steinberg D. The 94- to 97-kDa mouse
macrophage membrane protein that recognizes oxidized low
density lipoprotein and phosphatidylserine-rich
liposomes is identical to macrosialin, the mouse homologue of human
CD68. Proc Natl Acad Sci U S A. 1995;92:9580-9584.
40. Elomaa O, Kangas M, Sahlberg C, Tuukkanen J, Sormunen R, Liakka A, Thesleff I, Kraal G, Tryggvason K. Cloning of a novel bacteria-binding receptor structurally related to scavenger receptors and expressed in a subset of macrophages. Cell. 1995;80:603-609.[Medline] [Order article via Infotrieve]
41. Krieger M, Herz J. Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu Rev Biochem. 1994;63:601-637.[Medline] [Order article via Infotrieve]
42. Fraser I, Hughes D, Gordon S. Divalent cation-independent macrophage adhesion inhibited by monoclonal antibody to murine scavenger receptor. Nature. 1993;364:343-346.[Medline] [Order article via Infotrieve]
43. Murata Y, Behr SR, Kraemer FB. Regulation of macrophage lipoprotein lipase secretion by the scavenger receptor. Biochim Biophys Acta. 1988;972:17-24.[Medline] [Order article via Infotrieve]
44. Claus R, Fyrnys B, Deigner HP, Wolf G. Oxidized low density lipoprotein stimulates protein kinase C (PKC) and induces expression of PKC-isotypes via prostaglandin-H synthase in P388D1 macrophage-like cells. Biochemistry. 1996;35:4911-4922.[Medline] [Order article via Infotrieve]
45. Hug H, Sarre TF. Protein kinase C isoenzymes: divergence in signal transduction? Biochem J. 1993;291:329-343.
46.
Kusuhara M, Chait A, Cader A, Berk BC. Oxidized
LDL stimulates mitogen-activated protein kinases in smooth
muscle cells and macrophages. Arterioscler Thromb
Vasc Biol. 1997;17:141-148.
47.
Tsuboi A, Muramatsu M, Tsutsumi A, Arai K, Arai
N. Calcineurin activates transcription from the GM-CSF
promoter in synergy with either PKC or NF-
B/AP-1 in T cells.
Biochem Biophys Res Commun. 1994;199:1064-1072.[Medline]
[Order article via Infotrieve]
48.
Ares MPS, Kallin B, Eriksson P, Nilsson J.
Oxidized LDL induces transcription factor activator
protein-1 but inhibits activation of nuclear factor-
B in human
vascular smooth muscle cells. Arterioscler Thromb Vasc
Biol. 1995;15:1584-1590.
This article has been cited by other articles:
![]() |
Z. Yuan, T. Miyoshi, Y. Bao, J. P. Sheehan, A. H. Matsumoto, and W. Shi Microarray analysis of gene expression in mouse aorta reveals role of the calcium signaling pathway in control of atherosclerosis susceptibility Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1336 - H1343. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Chen, M. Riazy, E. M. Smith, C. G. Proud, U. P. Steinbrecher, and V. Duronio Oxidized LDL-Mediated Macrophage Survival Involves Elongation Factor-2 Kinase Arterioscler Thromb Vasc Biol, January 1, 2009; 29(1): 92 - 98. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Taketa, T. Matsumura, M. Yano, N. Ishii, T. Senokuchi, H. Motoshima, Y. Murata, S. Kim-Mitsuyama, T. Kawada, H. Itabe, et al. Oxidized Low Density Lipoprotein Activates Peroxisome Proliferator-activated Receptor-{alpha} (PPAR{alpha}) and PPAR{gamma} through MAPK-dependent COX-2 Expression in Macrophages J. Biol. Chem., April 11, 2008; 283(15): 9852 - 9862. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Preiss, D. Namgaladze, and B. Brune Critical role for classical PKC in activating Akt by phospholipase A2-modified LDL in monocytic cells Cardiovasc Res, March 1, 2007; 73(4): 833 - 840. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Rask-Madsen and G. L. King Proatherosclerotic Mechanisms Involving Protein Kinase C in Diabetes and Insulin Resistance Arterioscler Thromb Vasc Biol, March 1, 2005; 25(3): 487 - 496. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Senokuchi, T. Matsumura, M. Sakai, M. Yano, T. Taguchi, T. Matsuo, K. Sonoda, D. Kukidome, K. Imoto, T. Nishikawa, et al. Statins Suppress Oxidized Low Density Lipoprotein-induced Macrophage Proliferation by Inactivation of the Small G Protein-p38 MAPK Pathway J. Biol. Chem., February 25, 2005; 280(8): 6627 - 6633. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Lamharzi, C. B. Renard, F. Kramer, S. Pennathur, J. W. Heinecke, A. Chait, and K. E. Bornfeldt Hyperlipidemia in Concert With Hyperglycemia Stimulates the Proliferation of Macrophages in Atherosclerotic Lesions: Potential Role of Glucose-Oxidized LDL Diabetes, December 1, 2004; 53(12): 3217 - 3225. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Zettler, M. A. Prociuk, J. A. Austria, G. Zhong, and G. N. Pierce Oxidized Low-Density Lipoprotein Retards the Growth of Proliferating Cells by Inhibiting Nuclear Translocation of Cell Cycle Proteins Arterioscler Thromb Vasc Biol, April 1, 2004; 24(4): 727 - 732. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kawakami, A. Tanaka, T. Chiba, K. Nakajima, K. Shimokado, and M. Yoshida Remnant Lipoprotein-Induced Smooth Muscle Cell Proliferation Involves Epidermal Growth Factor Receptor Transactivation Circulation, November 25, 2003; 108(21): 2679 - 2688. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Hamilton Nondisposable materials, chronic inflammation, and adjuvant action J. Leukoc. Biol., June 1, 2003; 73(6): 702 - 712. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Hundal, B. S. Salh, J. W. Schrader, A. Gomez-Munoz, V. Duronio, and U. P. Steinbrecher Oxidized low density lipoprotein inhibits macrophage apoptosis through activation of the PI 3-kinase/PKB pathway J. Lipid Res., September 1, 2001; 42(9): 1483 - 1491. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q.-K. Tran, H. Watanabe, H.-Y. Le, L. Pan, M. Seto, K. Takeuchi, and K. Ohashi Myosin Light Chain Kinase Regulates Capacitative Ca2+ Entry in Human Monocytes/Macrophages Arterioscler Thromb Vasc Biol, April 1, 2001; 21(4): 509 - 515. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. B. Giardina, D. J. Tanner, and R. A. Khalil Oxidized-LDL Enhances Coronary Vasoconstriction by Increasing the Activity of Protein Kinase C Isoforms {{alpha}} and {{epsilon}} Hypertension, February 1, 2001; 37(2): 561 - 568. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Whitman, A. Daugherty, and S. R. Post Regulation of acetylated low density lipoprotein uptake in macrophages by pertussis toxin-sensitive G proteins J. Lipid Res., May 1, 2000; 41(5): 807 - 813. [Abstract] [Full Text] |
||||
![]() |
T. Biwa, M. Sakai, T. Matsumura, S. Kobori, K. Kaneko, A. Miyazaki, H. Hakamata, S. Horiuchi, and M. Shichiri Sites of Action of Protein Kinase C and Phosphatidylinositol 3-Kinase Are Distinct in Oxidized Low Density Lipoprotein-induced Macrophage Proliferation J. Biol. Chem., February 25, 2000; 275(8): 5810 - 5816. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Matsumura, M. Sakai, K. Matsuda, N. Furukawa, K. Kaneko, and M. Shichiri Cis-acting DNA Elements of Mouse Granulocyte/Macrophage Colony-stimulating Factor Gene Responsive to Oxidized Low Density Lipoprotein J. Biol. Chem., December 31, 1999; 274(53): 37665 - 37672. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. C. Gelissen, K.-A. Rye, A. J. Brown, R. T. Dean, and W. Jessup Oxysterol efflux from macrophage foam cells: the essential role of acceptor phospholipid J. Lipid Res., September 1, 1999; 40(9): 1636 - 1646. [Abstract] [Full Text] |
||||
![]() |
B. Metzler, C. Li, Y. Hu, G. Sturm, N. Ghaffari-Tabrizi, and Q. Xu LDL Stimulates Mitogen-Activated Protein Kinase Phosphatase-1 Expression, Independent of LDL Receptors, in Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, August 1, 1999; 19(8): 1862 - 1871. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sakai, T. Biwa, T. Matsumura, T. Takemura, H. Matsuda, Y. Anami, T. Sasahara, S. Kobori, and M. Shichiri Glucocorticoid Inhibits Oxidized LDL-Induced Macrophage Growth by Suppressing the Expression of Granulocyte/Macrophage Colony-Stimulating Factor Arterioscler Thromb Vasc Biol, July 1, 1999; 19(7): 1726 - 1733. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Martens, M. Lougheed, A. Gomez-Munoz, and U. P. Steinbrecher A Modification of Apolipoprotein B Accounts for Most of the Induction of Macrophage Growth by Oxidized Low Density Lipoprotein J. Biol. Chem., April 16, 1999; 274(16): 10903 - 10910. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Petit, P. Lesnik, C. Dachet, M. Moreau, and M. J. Chapman Tissue Factor Pathway Inhibitor Is Expressed by Human Monocyte–Derived Macrophages : Relationship to Tissue Factor Induction by Cholesterol and Oxidized LDL Arterioscler Thromb Vasc Biol, February 1, 1999; 19(2): 309 - 315. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Biwa, H. Hakamata, M. Sakai, A. Miyazaki, H. Suzuki, T. Kodama, M. Shichiri, and S. Horiuchi Induction of Murine Macrophage Growth by Oxidized Low Density Lipoprotein Is Mediated by Granulocyte Macrophage Colony-stimulating Factor J. Biol. Chem., October 23, 1998; 273(43): 28305 - 28313. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Zhao, J. Letterman, and B. M. Schreiber beta -Migrating Very Low Density Lipoprotein (beta VLDL) Activates Smooth Muscle Cell Mitogen-activated Protein (MAP) Kinase via G Protein-coupled Receptor-mediated Transactivation of the Epidermal Growth Factor (EGF) Receptor. EFFECT OF MAP KINASE ACTIVATION ON beta VLDL PLUS EGF-INDUCED CELL PROLIFERATION J. Biol. Chem., August 10, 2001; 276(33): 30579 - 30588. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |